{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:09:32Z","timestamp":1789765772645,"version":"4.0.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40\u201380 years; Hoehn &amp;amp; Yahr (H&amp;amp;Y) Stage I or II; time from diagnosis \u22642 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment na\u00efve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-na\u00efve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&amp;amp;Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society\u2014Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-na\u00efve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment na\u00efve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment na\u00efve).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    NCT03100149.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2021.705407","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:01:22Z","timestamp":1636023682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":81,"title":["A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data"],"prefix":"10.3389","volume":"12","author":[{"given":"Gennaro","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Boess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten I.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Mollenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Boulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Anzures-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamarie","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Nikolcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene G.","family":"Kinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner M.","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Ness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ostrowitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Simuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sevigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Umbricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azad","family":"Bonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PASADENA Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Prasinezumab Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized delayed-start trial of levodopa in Parkinson's disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"New Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/NDT.S2006","article-title":"Current approaches to the treatment of Parkinson's disease","volume":"4","author":"Jankovic","year":"2008","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00023210-200013050-00005","article-title":"Involvement of non-dopaminergic pathways in Parkinson's disease","volume":"13","author":"Bonnet","year":"2000","journal-title":"CNS Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fneur.2018.00455","article-title":"On cell loss and selective vulnerability of neuronal populations in Parkinson's disease","volume":"9","author":"Giguere","year":"2018","journal-title":"Front Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp.52.Suppl.29","article-title":"The on-off phenomenon","volume":"52","author":"Lees","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2047-9158-4-3","article-title":"Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future","volume":"4","author":"Jenner","year":"2015","journal-title":"Transl Neurodegener."},{"key":"B9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/erp.11.106","article-title":"Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors","volume":"12","author":"Martinez-Martin","year":"2012","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Prim."},{"key":"B14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology","volume":"42","author":"Del Tredici","year":"2016","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-021-02329-9","article-title":"The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy","volume":"142","author":"Moors","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","article-title":"Widespread transneuronal propagation of \u03b1-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease","volume":"13","author":"Rey","year":"2016","journal-title":"J Exp Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science."},{"key":"B22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am J Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI43366","article-title":"\u03b1-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells","volume":"121","author":"Hansen","year":"2011","journal-title":"J Clin Investig"},{"key":"B24","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J Exp Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron."},{"key":"B27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron."},{"key":"B28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s40478-019-0859-3","article-title":"alpha-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb","volume":"7","author":"Rey","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science."},{"key":"B30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"Alpha-synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease","volume":"364","author":"Ibanez","year":"2004","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/ajmg.b.30758","article-title":"Genetic association between alpha-synuclein and idiopathic Parkinson's disease","author":"Kay","year":"2008","journal-title":"Am J Med Genet Part B Neuropsychiatric Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0891988710383572","article-title":"The genetics of Parkinson disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J Geriatr Psychiatry Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/mds.23948","article-title":"Parkinson's disease and alpha-synuclein expression","volume":"26","author":"Devine","year":"2011","journal-title":"Mov Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1474-4422(19)30140-1","article-title":"Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study","volume":"18","author":"Wilson","year":"2019","journal-title":"Lancet Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","article-title":"In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study","volume":"17","author":"Knudsen","year":"2018","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron."},{"key":"B41","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fnins.2018.00452","article-title":"Region-specific effects of immunotherapy with antibodies targeting alpha-synuclein in a transgenic model of synucleinopathy","volume":"12","author":"Kallab","year":"2018","journal-title":"Front Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord."},{"key":"B46","unstructured":"A Landmark Study of Parkinson's Disease2018"},{"key":"B47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov Disord."},{"key":"B48","unstructured":"NCT03100149: A Study to Evaluate the Efficacy of Prasinezumab (RO7046015\/PRX002) in Participants with Early Parkinson's Disease (PASADENA)2017"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41746-020-0305-8","article-title":"Outcome measures based on digital health technology sensor data: data- and patient-centric approaches","volume":"3","author":"Taylor","year":"2020","journal-title":"NPJ Digit Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1007\/s13311-019-00788-3","article-title":"Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington's disease (HD)","volume":"16","author":"Lipsmeier","year":"2019","journal-title":"Neurotherapeutics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale","volume":"32","author":"Horvath","year":"2017","journal-title":"Mov Disord."},{"key":"B54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","article-title":"The Parkinson progression marker initiative (PPMI)","volume":"95","year":"2011","journal-title":"Prog Neurobiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"90.e1","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes","volume":"10","author":"Rascol","year":"2011","journal-title":"Lancet Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","year":"2002","journal-title":"Arch Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/mds.26354","article-title":"Disease-modifying strategies for Parkinson's disease","volume":"30","author":"Kalia","year":"2015","journal-title":"Mov Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1212\/WNL.0b013e3182a6cbd5","article-title":"Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort","volume":"81","author":"Mollenhauer","year":"2013","journal-title":"Neurology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","article-title":"Parkinson Study Group","volume":"51","year":"1994","journal-title":"Arch Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2047-9158-2-19","article-title":"Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease","volume":"2","author":"Teo","year":"2013","journal-title":"Transl Neurodegener."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41531-016-0006-9","article-title":"Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?","volume":"3","author":"Qamar","year":"2017","journal-title":"NPJ Parkinsons Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract."},{"key":"B65","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7861\/clinmedicine.16-4-371","article-title":"Imaging in Parkinson's disease","volume":"16","author":"Pagano","year":"2016","journal-title":"Clin Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/brain\/awr233","article-title":"Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease","volume":"134","author":"Nandhagopal","year":"2011","journal-title":"Brain."},{"key":"B67","first-page":"1694","article-title":"Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline","volume":"45","author":"Schwarz","year":"2004","journal-title":"J Nucl Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/mds.25628","article-title":"Quantitative wearable sensors for objective assessment of Parkinson's disease","volume":"28","author":"Maetzler","year":"2013","journal-title":"Mov Disord."},{"key":"B69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00702-015-1439-8","article-title":"Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease","volume":"123","author":"Ossig","year":"2016","journal-title":"J Neural Transm."},{"key":"B70","volume-title":"Successful Passive Monitoring of Early-Stage Parkinson's Disease Patient Mobility in Phase I RG7935\/PRX002 Clinical Trial with Smartphone Sensors","author":"Lipsmeier","year":"2017"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.27376","article-title":"Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial","volume":"33","author":"Lipsmeier","year":"2018","journal-title":"Mov Disord."},{"key":"B72","first-page":"92","article-title":"Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients (P4.7-005)","author":"Lipsmeier","year":"2019","journal-title":"Neurology."},{"key":"B73","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1212\/WNL.0b013e3182a9f449","article-title":"Alpha-synuclein in cutaneous autonomic nerves","volume":"81","author":"Wang","year":"2013","journal-title":"Neurology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio","year":"2014","journal-title":"Neurology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horvath","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"key":"B77","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41531-017-0021-5","article-title":"Use of a self-rating scale of the nature and severity of symptoms in Parkinson's Disease (PRO-PD): Correlation with quality of life and existing scales of disease severity","volume":"3","author":"Mischley","year":"2017","journal-title":"NPJ Parkinsons Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1093\/brain\/awaa226","article-title":"Long duration response in Parkinson's disease: levodopa revisited","volume":"143","author":"Poewe","year":"2020","journal-title":"Brain J Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fneur.2020.00395","article-title":"Clinical and imaging markers of prodromal Parkinson's disease","volume":"11","author":"Hustad","year":"2020","journal-title":"Front Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e697","DOI":"10.1097\/PR9.0000000000000697","article-title":"Designing and conducting proof-of-concept chronic pain analgesic clinical trials","volume":"4","author":"Campbell","year":"2019","journal-title":"Pain Rep."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.705407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:01:28Z","timestamp":1636023688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.705407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":80,"alternative-id":["10.3389\/fneur.2021.705407"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.705407","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.09.21251911","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"705407"}}